BostonGene and Takeda collaborate on research studies focused on immuno-oncology. Their partnership aims to enhance clinical trial design, improve patient selection, and identify biomarkers for treatment efficacy and adverse effects.
Takeda will utilize BostonGene’s AI-powered multiomics platform in early-stage clinical trials. BostonGene’s proprietary computational platforms will analyze clinical and laboratory data. They will perform sophisticated multiomic analytics, including bioinformatics analysis on flow cytometry, RNA-seq, and proteomics data.
The partnership leverages advanced technology to enhance Takeda’s oncology research. By analyzing multiomic profiles of cancer patients, the collaboration aims to gain insights into the biology and mechanisms of investigational therapies.
BostonGene’s multiomic analytics will improve patient selection processes and identify mechanistic signatures associated with treatment response. This will drive the development of innovative cancer treatments.
BostonGene is dedicated to advancing and personalizing cancer medicine. Through its AI-powered multiomics platform, it digitizes and analyzes molecular profiles of cancer patients. The company’s software solutions, cancer library, and bioanalytics enable the discovery of multiparametric signatures, target identification, and treatment recommendations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
